临床肺科杂志
臨床肺科雜誌
림상폐과잡지
Journal of Clinical Pulmonary Medicine
2015年
12期
2153-2155,2156
,共4页
郭小渝%郑儒君%李俊英%余春华%符琰
郭小渝%鄭儒君%李俊英%餘春華%符琰
곽소투%정유군%리준영%여춘화%부염
阿瑞匹坦%肺癌%化疗%不良反应
阿瑞匹坦%肺癌%化療%不良反應
아서필탄%폐암%화료%불량반응
Aprepitant%lung cancer%chemotherapy%adverse reaction
目的:观察肺癌患者采用阿瑞匹坦口服,化疗诱导性恶心和呕吐的效果及不良反应。方法采用随机对照,将160例患者随机分为A和B两组,阿瑞匹坦组( A组)采用阿瑞匹坦、托烷司琼联合地塞米松,标准方案组(B组)采用托烷司琼联合地塞米松,两组患者比较恶心、呕吐及治疗相关不良反应的发生率。结果阿瑞匹坦组患者恶心( Z =-2.028)及呕吐( Z =-2.151)反应程度明显低于和标准方案组( P <0.05);阿瑞匹坦组对恶心、呕吐的有效控制率(96.2%、97.5%)明显高于标准方案组(81.2%、83.8%)(P<0.05),差异有统计学意义。两种方案其它主要不良反应如厌食、便秘、疲倦、呃逆、头晕、口干等发生率差异均无统计学意义(P>0.05)。结论肺癌患者化疗服用阿瑞匹坦胶囊,能减轻化疗引起的恶心、呕吐等不良反应,而且具有很好的耐受性。
目的:觀察肺癌患者採用阿瑞匹坦口服,化療誘導性噁心和嘔吐的效果及不良反應。方法採用隨機對照,將160例患者隨機分為A和B兩組,阿瑞匹坦組( A組)採用阿瑞匹坦、託烷司瓊聯閤地塞米鬆,標準方案組(B組)採用託烷司瓊聯閤地塞米鬆,兩組患者比較噁心、嘔吐及治療相關不良反應的髮生率。結果阿瑞匹坦組患者噁心( Z =-2.028)及嘔吐( Z =-2.151)反應程度明顯低于和標準方案組( P <0.05);阿瑞匹坦組對噁心、嘔吐的有效控製率(96.2%、97.5%)明顯高于標準方案組(81.2%、83.8%)(P<0.05),差異有統計學意義。兩種方案其它主要不良反應如厭食、便祕、疲倦、呃逆、頭暈、口榦等髮生率差異均無統計學意義(P>0.05)。結論肺癌患者化療服用阿瑞匹坦膠囊,能減輕化療引起的噁心、嘔吐等不良反應,而且具有很好的耐受性。
목적:관찰폐암환자채용아서필탄구복,화료유도성악심화구토적효과급불량반응。방법채용수궤대조,장160례환자수궤분위A화B량조,아서필탄조( A조)채용아서필탄、탁완사경연합지새미송,표준방안조(B조)채용탁완사경연합지새미송,량조환자비교악심、구토급치료상관불량반응적발생솔。결과아서필탄조환자악심( Z =-2.028)급구토( Z =-2.151)반응정도명현저우화표준방안조( P <0.05);아서필탄조대악심、구토적유효공제솔(96.2%、97.5%)명현고우표준방안조(81.2%、83.8%)(P<0.05),차이유통계학의의。량충방안기타주요불량반응여염식、편비、피권、애역、두훈、구간등발생솔차이균무통계학의의(P>0.05)。결론폐암환자화료복용아서필탄효낭,능감경화료인기적악심、구토등불량반응,이차구유흔호적내수성。
Objective To investigate the effect of chemotherapy-induced nausea and vomiting and adverse reaction of Aprepitant utilized in patient with lung cancer. Methods 160 patients were randomly divided into the group A, which was given Aprepitant, tropisetron and hexadecadrol, and the group B given ropisetron and hexadec-adrol. Nausea, vomiting and treat correlated adverse reaction were compared between the two groups. Results The extents of reaction of nausea and vomiting in the group A were obviously lower than those in the group B (P<0. 05). The valid control rates of nausea and vomiting were 96. 2% and 97. 5% in the group A, which were obviously higher than those in the group B (81. 2% and 83. 8%) (P<0. 05). There was no significant difference in the main adverse reactions such as anorexia, constipation, fatigue, hiccough, dizziness and dry mouth between the two groups. Con-clusion Aprepitant can ease off the adverse reactions such as nausea and vomiting induced by chemotherapy in the treatment of patient with lung cancer.